Volume 14, No 5, Oct 2004
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 14 Issue 5, October 2004: 359-372
REVIEWS
Following a TRAIL: Update on a ligand and its five receptors
Fiona C. Kimberley1, Gavin R. Screaton2,*
1Weatherall Institute of Molecular Medicine, Human Immunology Unit, John Radcliffe Hospital, Oxford OX3 9DS, UK
2Department of Medicine, Hammersmith Hospital, Imperial College, Du Cane Road, London W12 0NN UK.
Correspondence: Gavin R. Screaton(g.screaton@imperial.ac.uk)
Identification of tumour necrosis factor apoptosis inducing ligand (TRAIL), a TNF family ligand, sparked a torrent of research, following an initial observation that it could kill tumour cells, but spare normal cells. Almost a decade after its discovery, and with five known receptors, the true physiological role of TRAIL is still debated and its anti-tumorigenic properties limited by potential toxicity. This review takes a comprehensive look at the story of this enigmatic ligand, addressing its remaining potential as a therapeutic and providing an overview of the TRAIL receptors themselves.
FULL TEXT | PDF
Browse 1641
